Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps

Trial Profile

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Sinusitis
  • Focus Therapeutic Use
  • Sponsors OptiNose
  • Most Recent Events

    • 10 Dec 2018 According to an OptiNose media release, first patient has been enrolled in the trial.
    • 10 Dec 2018 Status changed from planning to recruiting, according to an OptiNose media release.
    • 19 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top